There is no excerpt because this is a protected post.Continue reading
This post is protected. To view it, enter the password below!
September was designated as National Blood Cancer Awareness Month in 2010 by the United States Congress. Approximately every 3 minutes one person in the United States is diagnosed with a blood cancer. That means that during September, Blood Cancer Awareness Month, more than 14,000 people will be informed that they have one of these terrible diseases.
Blood cancers are a group of diseases that affect the production and function of blood cells. The three main types are leukemia (found in blood and bone marrow), lymphoma (affects the body’s lymphatic system) and myeloma (impacts plasma cells). Nearly 172,000 people in the U.S. are living with a blood cancer, according to Kevin Radelet, executive director, Leukemia Research Foundation.
In recognition of Blood Cancer Awareness Month, the Leukemia Research Foundation is conducting a social media initiative called The Heroes Among Us to increase awareness about ALL blood cancers, including leukemia, lymphoma, multiple myeloma, and myelodysplastic syndromes.
Several buildings in downtown Chicago — LRF is located in Northfield, IL — will “light up orange” in recognition of Blood Cancer Awareness Month. Click here for details.
Here’s how you can participate:
? Share on social media channels online using hashtags: #LRFHeroes?and/or #HeroesWearOrange
? Share the link to the heroes stories with friends, family members and colleagues
? Buy a bag of orange ribbons and share them!?Send an email?to request ribbons
? Please donate today?to help LRF continue to raise awareness and funding for research and patient programs.
? For other ways to get involved, sign up for events, or volunteer, please click here.
Headquartered in Northfield, IL., the Leukemia Research Foundation is dedicated to conquering all blood cancers by funding research into their causes and cures and enriching the quality of life of those touched by these diseases. For more information, visit www.allbloodcancers.org or call 847-424-0600.
Copy reprinted by permission of LRF.org; excerpt by permission of PRnewswire
Got Questions? We have Answers! Contact us at CriteriumBlog@criteriuminc.com
As if Breast Cancer or Brain Cancer alone were not enough to combat — patients with both now?have new hope in light of fledgling research that is showing progress.
Once breast cancer metastasizes into other areas of the body, particularly the brain, it becomes much more dangerous. And while the National Cancer Institute spends more than $500 million dollars per year on breast cancer research, only two to five percent of this funding goes to study how the disease spreads.
A clinical trial is open nationwide through the Academic Breast Cancer Consortium (ABRCC), giving access to an exciting novel drug therapy combination. The tucatinib, palbocilib and letrozole trial is coordinated by ABRCC and currently open for enrollment at the University of Colorado Cancer Center; University of Texas Health and Science Center in San Antonio, TX; Stony Brook University, NY; University of Arizona, Tucson, AZ; and University of New Mexico, Albuquerque, NM and will also be accruing patients at Northwestern University, Chicago, IL.
There are three well-established predictive markers of breast cancer. They are estrogen receptors (ER), progesterone receptors (PR), and the growth factor receptor HER2, these receptors may be blocked with targeted drugs to stop cancer growth. Breast cancers lacking these three markers are referred to as ?triple-negative? but clinicians and scientists are quickly learning more about cancers that have all three receptors, which are often called ?triple-positive.? There are treatments against each target individually, but when multiple drivers are present, as in ?triple-positive? breast cancer, blocking one often results in cancer nimbly switching to driving its growth with the other two.
The study combines tucatinib, which inhibits HER2, with letrozole targeting ER and PR hormone receptors, and the drug palbociclib, which targets CDK proteins that help cancer cells rush through the process of replication. The three had not been tried together until Elena Shagisultanova, MD, PhD, a breast cancer specialist at UCH, hypothesized there could be a way to target all three drivers at the same time with better results than targeting combinations of any two.
?When metastatic cancer spreads to the brain, it can be especially challenging,? says Dr Peter Kabos, the National Medical Director of the Academic Breast Cancer Consortium (ABRCC) and the Kabos Research Lab for Breast Cancer at UC Denver. ?Many medications aren?t effective in the brain, but exciting early clinical trial data for tucatinib shows that it may be one of the drugs that can penetrate the blood-brain barrier to combat brain metastases.
The trial is funded by the Pfizer ASPIRE Award in Breast Cancer Research. Cascadian Therapeutics and Pfizer are providing the study drugs tucatinib and palbociclib. For more information about trial eligibility and participation, contact email@example.com or firstname.lastname@example.org
Article excerpted with permission from the University of Colorado Cancer Center blog — for the complete story, click here.